Bisphosphonates and denosumab are well-established therapies to reduce the frequency and severity of skeletal-related events in patients with bone metastasis. However, the analgesic effect of these medications on bone pain is uncertain.Watch movie online The Transporter Refueled (2015)

Evidence to support an analgesic role for bisphosphonates and denosumab is weak. Bisphosphonates and denosumab appear to be beneficial in preventing pain by delaying the onset of bone pain rather than by producing an analgesic effect per se.

Más Información

Porta-Sales J Garzón-Rodríguez C, Llorens-Torromé S, Brunelli C, Pigni A, Caraceni A.